Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone.
To test the hypothesis that bone metastasis is related to the rate of bone remodeling, we have examined the effect of enhanced bone resorption on the growth of spontaneously metastatic Walker 256 (W256) cancer cells. Bone resorption was stimulated in male Fischer rats by injecting Rice H-500 Leydig tumor cells subcutaneously. The resorptive response of the skeleton was confirmed in a pilot study by evaluating parameters of bone morphometry after 4, 7 and 10 days of tumor burden. The distal femoral epiphyses had 35 +/- 10% more osteoclast surface, 83 +/- 11% less osteoblast surface, and 46 +/- 5% less trabecular bone after 10 days of tumor burden, compared to non-tumor-bearing controls. To evaluate the effect of Leydig tumor-induced bone resorption on the growth response of W256 cells, 20 rats were injected intramuscularly with 2 x 10(7) W256 cells, and 20 rats were vehicle-injected. Two days later, 10 rats from each group were injected subcutaneously with Leydig tumor cells. Twelve days after W256/vehicle injection, rats were injected with [3H]thymidine, killed 2 h later, and their femurs, liver, lungs and kidneys were processed for histology. In rats injected with Leydig tumor cells only, enhanced bone resorption was confirmed by a 40 +/- 4% increase in serum calcium concentration, a 48 +/- 8% decrease in trabecular bone content, and a 72 +/- 15% decrease in osteoblast surface, compared with non-tumor-bearing rats. Metastatic W256 cells adjacent to trabecular bone in Leydig tumor-bearing rats had a 56 +/- 18% greater relative [3H]thymidine labeling index (TdR) than did W256 cells in the bones of non-Leydig tumor-bearing rats. The TdRs of W256 cells in the liver, lungs, and kidneys were not affected by Leydig tumor burden. In this model, enhanced bone resorption was associated with the selective growth promotion of metastatic W256 cells in bone, suggesting the existence of a bone-derived factor which is mitogenic to W256 cells.
Kostenuik
P J
PJ
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Singh
G
G
Suyama
K L
KL
Orr
F W
FW
D000818:Animals; D001822:Body Burden; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000556:secondary*; D001862:Bone Resorption / Q000503:physiopathology*; D002118:Calcium / Q000097:blood; D002279:Carcinoma 256, Walker / Q000378:metabolism / Q000473:pathology* / Q000556:secondary*; D002455:Cell Division / Q000502:physiology; D007984:Leydig Cell Tumor / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D009368:Neoplasm Transplantation; D010865:Pilot Projects; D051381:Rats; D011916:Rats, Inbred F344; D013736:Testicular Neoplasms / Q000473:pathology; D013936:Thymidine / Q000493:pharmacokinetics; D014316:Tritium
D014316:Tritium; D002118:Calcium; D013936:Thymidine